Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 1994

A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina.

BACKGROUND Several molecular-genetic alterations in endometrial cancers, including aneuploidy and aberrant expression of p53 and HER-2/neu, have been associated with poor prognosis. To determine the importance of molecular-genetic factors relative to more traditional surgical-pathologic prognostic factors, a multivariable analysis was performed. METHODS Immunohistochemical staining for p53, HER-2/neu, estrogen receptor, progesterone receptor, and epidermal growth factor receptor was performed on frozen sections from 100 primary endometrial cancers. DNA ploidy was determined using computerized image analysis of Feulgen-stained touch preparations. In addition, information regarding surgical-pathologic features of the cancers was obtained. Univariable analysis was performed followed by multivariable analysis using Cox's proportional hazards model to identify variables predictive of poor prognosis. RESULTS With univariable analysis, race, histologic type, stage, grade, myometrial invasion, estrogen receptor, progesterone receptor, ploidy, p53 and HER-2/neu were predictive of the presence of persistent or recurrent disease. In the multivariable analysis, only International Federation of Gynecology and Obstetrics stage (P = 0.005), grade (P = 0.005), myometrial invasion (P = 0.024), and ploidy (P = 0.028) were significant. CONCLUSIONS Among molecular-genetic prognostic factors, DNA ploidy was the most strongly predictive of persistent or recurrent disease.

UI MeSH Term Description Entries
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009856 Oncogene Proteins, Viral Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities. Viral Oncogene Proteins,Viral Transforming Proteins,v-onc Proteins,Transforming Proteins, Viral,v onc Proteins
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005260 Female Females

Related Publications

A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
May 2009, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
February 1990, Archives of pathology & laboratory medicine,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
May 1995, Obstetrics and gynecology,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
November 1992, Gynecologic oncology,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
December 1999, Experimental and molecular pathology,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
December 1992, Analytical and quantitative cytology and histology,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
January 1996, Cancer letters,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
April 1994, Annals of surgery,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
April 1995, Annals of surgery,
A S Lukes, and M F Kohler, and C F Pieper, and B J Kerns, and R Bentley, and G C Rodriguez, and J T Soper, and D L Clarke-Pearson, and R C Bast, and A Berchuck
May 1995, Journal of surgical oncology,
Copied contents to your clipboard!